Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response

BACKGROUND: High plasma osteopontin (OPN) has been linked to tumour hypoxia, metastasis, and poor prognosis. This study aims to assess whether plasma osteopontin was a biomarker of increasing progression within prostate cancer (PCa) prognostic groups and whether it reflected treatment response to lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Thoms, J W, Dal Pra, A, Anborgh, P H, Christensen, E, Fleshner, N, Menard, C, Chadwick, K, Milosevic, M, Catton, C, Pintilie, M, Chambers, A F, Bristow, R G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425969/
https://www.ncbi.nlm.nih.gov/pubmed/22871886
http://dx.doi.org/10.1038/bjc.2012.345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425969/
https://www.ncbi.nlm.nih.gov/pubmed/22871886
http://dx.doi.org/10.1038/bjc.2012.345

Ejemplares similares